Bertis Establishes U.S. Operations to Bring Novel Proteomics-Based Diagnostics

to the U.S. Market

As a leading proteomics technology company in Asia, Bertis plans to bring its unique proteomic and data science-based diagnostics tests

to clients in the U.S.

SEOUL, KOREA - Oct. 11, 2022 – Bertis Inc., a South Korean proteomic-based precision medicine technology company, announced today it has established a U.S.-based wholly-owned entity to expand the company’s global presence and primarily provide access to the growing U.S. clinical testing market.

The company’s U.S. subsidiary, called Bertis Bioscience, is incorporated in Delaware, and aims to establish a San Diego based CLIA-certified lab facility in early Q4, 2022 to offer its expanding array of highly differentiated proteomics-based screening and diagnostic tests, as well as an analysis platform for integration of multi-omics data.

Proteomics, the study of proteins in the human body, has emerged as a promising field in medicine, particularly for its potential to identify subtypes of cancers and match patients with the most appropriate treatment strategy. Even though the cancer survival rate in the U.S. has increased over the past 28 years, some types of cancer are still difficult to detect at early stages, with no standard early diagnosis method. Proteomics has also been in the spotlight as the U.S. Cancer Moonshot initiative promoted a proteome consortium to encourage international collaboration and investment across countries in cancer research and treatment.

Bertis has established a foundation for precision medicine by developing diagnostic solutions based on technology that combines proteomics and AI, which has enabled the company to emerge as a leader in proteomics and bioinformatics in Asia. The company has successfully commercialized in South Korea MASTOCHECKTM, the world’s first proteomics-based breast cancer blood test solution.

In Korea, the solution has been used at over 170 health clinics and hospitals nationwide since marketing approval as an in vitro diagnostic medical device from the Ministry of Food and Drug Safety in January 2019. Bertis has gained a foothold into the Asian market by recently signing a contract with one of Singapore’s largest medical groups, Raffles Medical Group, to supply MASTOCHECKTM. Through this contract, MASTOCHECKTM will be introduced Raffles Breast Centre, Raffles Health Screeners, and over 30 Raffles Medical clinics in Singapore.

“We are excited to establish Bertis Bioscience in the U.S. We believe Bertis' unique and powerful approach to proteomics-based precision medicine will positively impact medical professionals and patients in the U.S. as it has in Asia,” said Seungman Han, Bertis founder and co-CEO. “With the San Diego site underway, Bertis aims to build on its success in South Korea and Asia and become a trusted partner to medical professionals and patients in the U.S. aiming to rapidly and effectively identify and treat a range of life-threatening diseases.”

The company is also developing a novel artificial intelligence and machine learning approach to maximize the utilization of protein information by discovering the ‘dark matter’ of the proteome, which is currently not accessible. Bertis’ unique and expanding expertise in analyzing and interpreting the proteome is expected to enable the company to expand into additional applications and diseases where there are high unmet medical needs in detection and treatment, such as ovarian cancer and pancreatic cancer.

Recently, Bertis’ research team presented protein biomarkers for early diagnosis of high-grade serous ovarian cancer (HGSOC) with 95% accuracy. The results of this study were published in the September issue of the Journal of Proteome Research by the American Chemical Society.

In this study, the research team identified 18 candidate proteins after quantifying 1,847 serum proteins, the highest number ever reported as ovarian cancer biomarker research results, through Bertis’ technology platform to discover biomarker candidates. As a result of developing and evaluating a predictive model, the accuracy of the diagnostic value for stages 1 to 3 HGSOC was 95% (sensitivity 100%, specificity 91%) when 18 candidate proteins were combined with multiple biomarkers.

For more information on Bertis Bioscience, please email us at info@bertisbio.com.